Pesticides Hazardous Hotspots: Empirical Evidences from North India.

The pesticide use in Indian agriculture showed a declining trend in the late 1990s and early 2000s. Since 2007, pesticide use gained an upward trend. To study the pesticide use pattern and identify pesticide hotspots, we collected data from a sample of 1201 apple, rice, vegetable, and cotton growers from the temperate Kashmir Valley, subtropical Jammu, and Punjab. Our study provided some interesting empirical results: prophylactic pesticide applications in apple crop making it a pesticide guzzler [25.2 kg of active ingredient (ai)/ha] with use of riskiest carcinogen pesticides (9 kg of a.i/ha) and field use environmental impact quotient (FEIQ) (620.4/ha) being the highest, the Kashmir Valley is the "pesticide hottest spot", followed by cotton and rice areas of Punjab and vegetable cultivation in Jammu subtropics. Pesticides banned for use in vegetables, such as monocrotophos were also applied by farmers in vegetable crops. However, rice areas in Kashmir and Jammu were only treated with herbicides. The protective measures taken by farmers while mixing and applying pesticides were primitive, resulting in localized mild/moderate pesticide poisoning besides loss of consciousness. We also found that the official data on the pesticide use are underreported and hence unreliable. Our study shows that neither the pesticide use by mass nor the pesticide use frequency, in combination or alone, is the robust indicator to measure the pesticide hazardous hotspots; besides these, FEIQ and less hazardous pesticides that are not probable or possible carcinogen should be rather used in conjunction.

Dissipation patterns of the fungicide difenoconazole (25% EC) in apples grown in Kashmir, India.

Dissipation patterns were studied following two applications of difenoconazole (score 25% EC) at 300 and 600 g ai ha(-1) as single and double dose respectively on Golden Delicious and Starkrimson cultivars of apple. Samples were collected at 0, 3, 6, 9, 12 and 30 days (harvest) post treatment. Limit of detection (LOD) and limit of quantification (LOQ) were found to be 0.004 and 0.008 µg g(-1), respectively. Half-life periods for Golden Delicious were found to be 6.09 and 6.70 days, and for Starkrimson, these values were observed to be 5.34 and 5.80 days, at single and double doses, respectively. Difenoconazole residues dissipated below its LOQ of 0.008 µg g(-1) after 30 day post treatment at a single dose in both the cultivars. Waiting periods of 13.06 and 10.72 days are suggested for Golden Delicious and Starkrimson cultivars at a recommended dose of 300 g ai ha(-1), respectively.

The efficacy of accelerated, multiple, double-dose hepatitis B vaccine against hepatitis B virus infection in cancer patients receiving chemotherapy.

BACKGROUND: Hepatitis B virus (HBV) infection in cancer patients receiving chemotherapy carries high morbidity and mortality. Conventional hepatitis B vaccination with three doses at 0, 1, and 6 months apart is ineffective in prevention of HBV infection. OBJECTIVES: To compare the efficacy of accelerated, multiple, double-dose HB vaccine with conventional HB vaccine in cancer patients receiving chemotherapy (CT). METHODS: Patients of cancer who were planned for CT were screened for HBV markers (HBsAg, total anti-HB core, anti-HBs antibody and HBV DNA). Patients with negative HBV serum markers received HB vaccine in two groups. Group A received three double doses (40 µg) of recombinant HB vaccine at 0, 1, and 3 weeks before CT and additional three double doses post CT. Group B received HB vaccine (20 µg) at 0, 1, and 6 months. Efficacy of vaccine in the two groups was compared by anti-HBs titers achieved at 3, 6, and 9 months and by HBsAg positivity following CT at 1 year follow up. RESULTS: Protective anti-HBs titers (>10 mIU/mL) at 3, 6, and 9 months in group A and B was 41.1 %, 66.2 %, and 76% and 26 %, 37.7 %, and 49% respectively (p = 0.001). Seven of 454 (1.5%) patients in group A became HBsAg positive after vaccination compared to 19/472 (4.0%) in group B (p = 0.022). CONCLUSION: Accelerated, multiple, double-dose HB vaccine increases seroprotection and is more effective than conventional HB vaccine in preventing HBV infection.

Prevalence of gallstone disease in patients with type 2 diabetes and the risk factors in North Indian population: a case control study.

BACKGROUND: Age, female sex, and obesity are considered to be risk factors for gallstone disease. The role of type 2 diabetes (T2D) in gallstone formation is still uncertain, and data in Indians is limited. OBJECTIVES: This is a case-control study to determine the prevalence of gallstones (GS) in patients with T2D, risk factors, and the relative risk compared with subjects without diabetes, selected from the general population. METHODS: Among 450 cases with T2D of a ≥2-year duration, 377 (88.8 %) participated. Diagnosis of GS was made at ultrasonography and history of cholecystectomy for GS. Controls were selected from the general population and diabetes excluded by oral glucose tolerance test. Cases and controls were matched for age, gender, and body mass index (BMI). RESULTS: Gallstones were seen in 67 (17.7 %) cases compared to 40 (5.8 %) in controls (p = 0.001). Prevalence increased with increasing age with peak in the sixth decade (23.4 % in cases and 4.4 % in controls (p = 0.001) and was higher in women (27.9 %) in cases and (7.8 %) in controls, (p = 0.001). In univariate analysis, risk factors for GS included age, female sex, BMI, multiparity, family history of GS, and high triglycerides and cholesterol with low high-density lipoprotein cholesterol. In multivariate analysis, age, (relative risk [RR] 1.54, confidence interval [CI] 1.1-2.1), female sex (RR 1.6, CI 1.0-1.9), and BMI (RR 1.5, CI 1.3-2.5) were the independent risk factors in gallstone formation. CONCLUSION: Patients with T2D had higher probability of having GS compared to the general population. Increasing age, female sex, and higher BMI were independently associated with gallstone disease.

Occult hepatitis B virus infection as a cause of posttransfusion hepatitis in patients with cancers.

BACKGROUND: Prevalence of hepatitis B virus (HBV) infection is increased in patients of cancer with increased mortality. Multiple transfusions of blood and blood-related products are a potential source. AIMS: This study aims to assess the incidence of hepatitis B surface antigen (HBsAg) seroconversion in cancer patients receiving transfusion of blood or blood-related products and identify possible reasons for infection in these patients. MATERIAL AND METHODS: Patients of cancer receiving blood products, who were HBsAg-, anti-hepatitis B core (HBc)-, and HBV DNA-negative prior to transfusion, were tested for HBsAg by ELISA at 6, 12, and 24 weeks after the last transfusion. Blood donors were screened for HBsAg by ELISA. RESULTS: Twenty of 3,600 (0.56 %) blood donors tested positive for HBsAg and were rejected. Nine of 150 (6 %) cancer patients became HBsAg-positive posttransfusion which included seven patients who presented with acute hepatitis B and other two patients who remained HBsAg-positive without hepatitis. In 6/9 (66.6 %) patients, HBsAg positivity was related to blood transfusion as their corresponding blood donors on retesting the stored samples were positive for anti-HBc antibody and HBV DNA. In other three patients, the cause of their HBsAg positivity could not be ascertained. CONCLUSION: Occult HBV infection in blood donors is a potential source of posttransfusion HBV infection in recipients. Anti-HBc antibody and HBV DNA should be tested in blood donors especially when blood is given to cancer patients receiving chemotherapy.